Dynavax Technologies | Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -2.64B 2.46B 2025-09
Adma Biologics USD 431.19M 32.87M 2025-09
Agenus USD -274.14M 80.46M 2025-09
Amgen USD 9.62B 2.19B 2025-09
AstraZeneca USD 48.67B 2.78B 2025-12
Biogen USD 18.21B 573.5M 2025-09
BioMarin Pharmaceutical USD 6.06B 29.6M 2025-09
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Dynavax Technologies USD 534.14M 39.98M 2025-09
Gilead Sciences USD 22.62B 1.16B 2025-12
Glaxosmithkline GBP 21.7B 7.35B 2025-09
Merck USD 51.85B 2.79B 2025-09
Minerva Neurosciences USD -34.58M 2.47M 2025-09
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Novartis USD 44.75B 2.7B 2025-09
Pfizer USD 92.8B 4.11B 2025-09
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Roche Holding CHF 33.8B 758M 2025-12
Sarepta Therapeutics USD 1.32B 37.26M 2025-09
TG Therapeutics USD 607.22M 330.79M 2025-09
Vertex Pharmaceuticals USD 17.32B 143.4M 2025-09


Dynavax Technologies Capitale Sociale E Riserve - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.